A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkins Lymphoma

Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2021-11-03

250

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

To determine the impact of dose intensity on tumor response and survival in patients with HIV-associated non-Hodgkin's lymphoma (NHL). HIV-infected patients are at increased risk for developing intermediate and high-grade NHL. While combination chemotherapy for aggressive B-cell NHL in the absence of immunodeficiency is highly effective, the outcome of therapy for patients with AIDS-associated NHL has been disappointing. Treatment is frequently complicated by the occurrence of multiple opportunistic infections, as well as the presence of poor bone marrow reserve, making the administration of standard doses of chemotherapy difficult. A recent study was completed using a low-dose modification of the standard mBACOD (cyclophosphamide, doxorubicin, vincristine, bleomycin, dexamethasone, methotrexate ) treatment. A 46 percent response rate was observed in patients treated with this combination of chemotherapeutic agents, with a number of durable remissions and reduced toxicity when compared to previous experience with more standard treatments. A subsequent study showed similar effectiveness using a lower dose of methotrexate administered on day 15. It is hoped that the use of sargramostim (granulocyte-macrophage colony-stimulating factor; GM-CSF) will improve bone marrow function and allow for administration of a higher dose of chemotherapy.

CONDITIONS

Brief Title

A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma

Who Can Participate

Age: 12Years +

All Genders

Eligibility Criteria

Inclusion Criteria

Concurrent Medication:

Required:

PCP prophylaxis with Bactrim, aerosolized pentamidine, or dapsone.

Allowed:

ddI, except when patient is also taking allopurinol.

Patients must have the following:

Diagnosis of HIV seropositivity and non-Hodgkin's lymphoma.
Ability to give informed consent and willingness to comply with all procedures and visit schedule.
If between ages of 12 and 18 must receive care under direct supervision of a pediatric oncologist, and have consent of parent, guardian, or person with power of attorney.
Participation in clinical trials of other antiretroviral agents is at the discretion of the investigator and individual patient.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

Active opportunistic infection, excluding Mycobacterium avium complex, requiring antibiotic therapy.
Another prior or current malignancy, excepting curatively treated cervical or basal cell carcinoma.
Kaposi's sarcoma if rapidly progressive, with visceral involvement, or causing peripheral edema.
Primary central nervous system lymphoma.

Concurrent Medication:

Excluded:

Zidovudine (AZT) or any antiretroviral agent unless allowed by investigator. ddI is allowed except when also taking allopurinol.

Systemic myelosuppressive drugs, including trimethoprim/sulfamethoxazole (T/S), pyrimethamine/sulfa, or ganciclovir.

Patients with the following are excluded:

Active opportunistic infection, excluding Mycobacterium avium complex, requiring antibiotic therapy.
Another prior or current malignancy, excepting curatively treated cervical or basal cell carcinoma.
Kaposi's sarcoma if rapidly progressive, with visceral involvement, or causing peripheral edema.
Primary central nervous system lymphoma.

Prior Medication:

Excluded: